ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
Dow Jones
39.118,86
-0,12%
Euro vs US Dollar
1,07205
0,00%
Bitcoin
60.860,73
0,91%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Savient Pharmaceuticals (MM) (SVNTE)

  7. Savient Pharmaceuticals (MM) (SVNTE) News

SVNTE

Savient (SVNTE)

Savient Pharmaceuticals (MM)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SVNTE
DatumZeitQuelleÜberschriftSymbolFirma
26/01/200622h23Business WireSavient Pharmaceuticals Files Form 10-Q For Period Ended September 30, 2005; Meets Final Filing Deadline for All Late Reports ReNASDAQ:SVNTESavient Pharmaceuticals (MM)
23/01/200621h45Business WireSavient Pharmaceuticals Receives Additional Extension from NASDAQNASDAQ:SVNTESavient Pharmaceuticals (MM)
19/01/200623h19Business WireSavient Completes Restatement of 2004 and Prior Period Results; Amended and Initial Quarterly Reports for 2005 Expected to be FiNASDAQ:SVNTESavient Pharmaceuticals (MM)
10/01/200600h30Business WireSavient Pharmaceuticals Closes Sale of Delatestryl(R) Product to Indevus PharmaceuticalsNASDAQ:SVNTESavient Pharmaceuticals (MM)
04/01/200600h30Business WireSavient Pharmaceuticals Receives Two-Week Extension from NASDAQ Regarding Late FilingsNASDAQ:SVNTESavient Pharmaceuticals (MM)
02/12/200508h30PR Newswire (US)Barr, Organon and Savient Finalize Mircette(R) Settlement and AcquisitionNASDAQ:SVNTESavient Pharmaceuticals (MM)
18/11/200523h15Business WireSavient Receives Expected Nasdaq Notice Regarding Delay in Filing Third Quarter Form 10-QNASDAQ:SVNTESavient Pharmaceuticals (MM)
14/11/200514h01PR Newswire (US)Savient's Puricase(R) (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment-ResiNASDAQ:SVNTESavient Pharmaceuticals (MM)
07/11/200513h41Business WireSavient Pharmaceuticals Provides Business Update; Financial Overview and Recent Strategic DevelopmentsNASDAQ:SVNTESavient Pharmaceuticals (MM)
02/11/200512h30Business WireSavient Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare ConferenceNASDAQ:SVNTESavient Pharmaceuticals (MM)
02/11/200500h30Business WireSavient Pharmaceuticals to Provide Business Update on November 7, 2005NASDAQ:SVNTESavient Pharmaceuticals (MM)
31/10/200522h41Business WireCORRECTING and REPLACING Savient Pharmaceuticals Receives FDA Approval to Market Soltamox(TM); The First Oral Liquid Tamoxifen iNASDAQ:SVNTESavient Pharmaceuticals (MM)
31/10/200520h00Business WireSavient Pharmaceuticals Receives FDA Approval to Market Soltamox(R); The First Oral Liquid Tamoxifen in U.S.; U.K.-based LiquidsNASDAQ:SVNTESavient Pharmaceuticals (MM)
28/10/200521h18Business WireSavient Pharmaceuticals Receives Filing Extension from NasdaqNASDAQ:SVNTESavient Pharmaceuticals (MM)
26/10/200523h59Business WireSavient Pharmaceuticals Determines Periods Affected for Restatement Include Six Months Ended June 30, 2005 and Fiscal Years EndeNASDAQ:SVNTESavient Pharmaceuticals (MM)
22/10/200500h30Business WireSavient Pharmaceuticals, Inc. Announces Second Amended Complaint in Purported Class Action LawsuitNASDAQ:SVNTESavient Pharmaceuticals (MM)
14/10/200513h00Business WireSavient Pharmaceuticals, Inc. to Present at the Upcoming BIO Investor Forum 2005NASDAQ:SVNTESavient Pharmaceuticals (MM)
14/10/200512h30Business WireSavient Audit Committee Completes ReviewNASDAQ:SVNTESavient Pharmaceuticals (MM)
06/10/200500h30Business WireSavient Pharmaceuticals Announces CFO Management ChangeNASDAQ:SVNTESavient Pharmaceuticals (MM)
04/10/200500h30Business WireSavient Updates NASDAQ Hearing and Restatement StatusNASDAQ:SVNTESavient Pharmaceuticals (MM)
03/10/200512h30Business WireTwo Abstracts Highlighting Savient Pharmaceuticals' Puricase(R) Accepted for American College of Rheumatology Annual ScientificNASDAQ:SVNTESavient Pharmaceuticals (MM)
21/09/200513h10Business WireSavient Pharmaceuticals Files Citizens' Petition with the FDA for Oxandrin(R); Requests FDA to Not Approve Any ANDA Prior to ExpNASDAQ:SVNTESavient Pharmaceuticals (MM)
08/09/200514h30PR Newswire (US)Barr, Organon and Savient Announce Letter of Intent Regarding Mircette(R)NASDAQ:SVNTESavient Pharmaceuticals (MM)
19/08/200512h30Business WireSavient Receives Nasdaq Delisting Notice Related to Late Form 10-QNASDAQ:SVNTESavient Pharmaceuticals (MM)
 Showing the most relevant articles for your search:NASDAQ:SVNTE

Kürzlich von Ihnen besucht

LSE
COOL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten